Minerva Neurosciences | Betriebsaufwand



Operating Expenses Veränderung Datum
Acadia Pharmaceuticals USD 225.03M 118.93M 2025-03
Adma Biologics USD 80.47M 268K 2024-12
ALKERMES USD 292.72M 25.42M 2025-03
AstraZeneca USD 9.91B 2.94B 2025-03
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Cipla INR 55.01B 1.37B 2025-03
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 8.95M 3.68M 2024-12
CSL USD 5.72B 173M 2024-12
Dynavax Technologies USD 91.79M 18.13M 2025-03
Eli Lilly USD 7.32B 1.06B 2025-03
GlaxoSmithKline GBP 5.3B 2.12B 2025-03
Grifols EUR 1.6B 128.03M 2024-12
Halozyme Therapeutics USD 123.33M 819K 2025-03
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
J&J USD 8.26B 10.37B 2025-03
Merck USD 9.66B 1.67B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Pfizer USD 10.05B 8.12B 2025-03
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 8.32B 1.55B 2025-03
Takeda JPY 1.13T 51.15B 2025-03



Minerva Neurosciences Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Jul 2025.